First National Bank Sioux Falls lowered its position in Johnson & Johnson (NYSE:JNJ) by 9.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,660 shares of the company’s stock after selling 668 shares during the period. Johnson & Johnson comprises approximately 3.1% of First National Bank Sioux Falls’ holdings, making the stock its 7th largest position. First National Bank Sioux Falls’ holdings in Johnson & Johnson were worth $931,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $124,000. Lenox Wealth Management Inc. increased its holdings in shares of Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after purchasing an additional 24 shares during the period. Finally, Intercontinental Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $200,000. Institutional investors own 67.21% of the company’s stock.
Shares of JNJ stock opened at $125.10 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The firm has a market capitalization of $351,969.94, a price-to-earnings ratio of 320.77, a price-to-earnings-growth ratio of 2.09 and a beta of 0.77. Johnson & Johnson has a twelve month low of $120.95 and a twelve month high of $148.32.
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.69%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 861.54%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.19% of the stock is currently owned by corporate insiders.
JNJ has been the topic of a number of recent analyst reports. Jefferies Group set a $161.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Friday. Citigroup dropped their price objective on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a report on Tuesday, February 27th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective on the stock in a report on Thursday, January 11th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Finally, Stifel Nicolaus upped their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, January 24th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $146.06.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.